BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

375 related articles for article (PubMed ID: 14871456)

  • 1. Extracellular role of HMGB1 in inflammation and sepsis.
    Wang H; Yang H; Tracey KJ
    J Intern Med; 2004 Mar; 255(3):320-31. PubMed ID: 14871456
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structural basis for the proinflammatory cytokine activity of high mobility group box 1.
    Li J; Kokkola R; Tabibzadeh S; Yang R; Ochani M; Qiang X; Harris HE; Czura CJ; Wang H; Ulloa L; Wang H; Warren HS; Moldawer LL; Fink MP; Andersson U; Tracey KJ; Yang H
    Mol Med; 2003; 9(1-2):37-45. PubMed ID: 12765338
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HMGB1 as a potential therapeutic target.
    Wang H; Li W; Goldstein R; Tracey KJ; Sama AE
    Novartis Found Symp; 2007; 280():73-85; discussion 85-91, 160-4. PubMed ID: 17380789
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HMGB1 as a cytokine and therapeutic target.
    Yang H; Wang H; Czura CJ; Tracey KJ
    J Endotoxin Res; 2002; 8(6):469-72. PubMed ID: 12697092
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PACAP inhibit the release and cytokine activity of HMGB1 and improve the survival during lethal endotoxemia.
    Tang Y; Lv B; Wang H; Xiao X; Zuo X
    Int Immunopharmacol; 2008 Dec; 8(12):1646-51. PubMed ID: 18713653
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bench to bedside: HMGB1-a novel proinflammatory cytokine and potential therapeutic target for septic patients in the emergency department.
    Sama AE; D'Amore J; Ward MF; Chen G; Wang H
    Acad Emerg Med; 2004 Aug; 11(8):867-73. PubMed ID: 15289194
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HMGB1 in sepsis.
    Andersson U; Tracey KJ
    Scand J Infect Dis; 2003; 35(9):577-84. PubMed ID: 14620138
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HMGB1 as a DNA-binding cytokine.
    Andersson U; Erlandsson-Harris H; Yang H; Tracey KJ
    J Leukoc Biol; 2002 Dec; 72(6):1084-91. PubMed ID: 12488489
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ameliorative Effect of Aspalathin and Nothofagin from Rooibos (Aspalathus linearis) on HMGB1-Induced Septic Responses In Vitro and In Vivo.
    Lee W; Kim KM; Bae JS
    Am J Chin Med; 2015; 43(5):991-1012. PubMed ID: 26224030
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of HMGB1 in cardiovascular diseases.
    Li W; Sama AE; Wang H
    Curr Opin Pharmacol; 2006 Apr; 6(2):130-5. PubMed ID: 16487750
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-septic effects of glyceollins in HMGB1-induced inflammatory responses in vitro and in vivo.
    Lee W; Ku SK; Lee YM; Bae JS
    Food Chem Toxicol; 2014 Jan; 63():1-8. PubMed ID: 24184598
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High mobility group box-1 as a therapeutic target downstream of tumor necrosis factor.
    Czura CJ; Yang H; Tracey KJ
    J Infect Dis; 2003 Jun; 187 Suppl 2():S391-6. PubMed ID: 12792856
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Persistent elevation of high mobility group box-1 protein (HMGB1) in patients with severe sepsis and septic shock.
    Sundén-Cullberg J; Norrby-Teglund A; Rouhiainen A; Rauvala H; Herman G; Tracey KJ; Lee ML; Andersson J; Tokics L; Treutiger CJ
    Crit Care Med; 2005 Mar; 33(3):564-73. PubMed ID: 15753748
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibitory Effect of Three Diketopiperazines from Marine-Derived Bacteria on HMGB1-Induced Septic Responses in Vitro and in Vivo.
    Lee W; Ku SK; Park S; Kim KM; Choi H; Bae JS
    Am J Chin Med; 2016; 44(6):1145-1166. PubMed ID: 27627916
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Delayed administration of D-Ala2-D-Leu5-enkephalin, a delta-opioid receptor agonist, improves survival in a rat model of sepsis.
    Tang CW; Feng WM; Du HM; Bao Y; Zhu M
    Tohoku J Exp Med; 2011 May; 224(1):69-76. PubMed ID: 21551984
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High mobility group box 1 protein as a late-acting mediator of acute lung inflammation.
    Lutz W; Stetkiewicz J
    Int J Occup Med Environ Health; 2004; 17(2):245-54. PubMed ID: 15387080
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic targeting of HMGB1 during experimental sepsis modulates the inflammatory cytokine profile to one associated with improved clinical outcomes.
    Stevens NE; Chapman MJ; Fraser CK; Kuchel TR; Hayball JD; Diener KR
    Sci Rep; 2017 Jul; 7(1):5850. PubMed ID: 28724977
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Heme-oxygenase-1 induction and carbon monoxide-releasing molecule inhibit lipopolysaccharide (LPS)-induced high-mobility group box 1 release in vitro and improve survival of mice in LPS- and cecal ligation and puncture-induced sepsis model in vivo.
    Tsoyi K; Lee TY; Lee YS; Kim HJ; Seo HG; Lee JH; Chang KC
    Mol Pharmacol; 2009 Jul; 76(1):173-82. PubMed ID: 19366789
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ameliorative effect of a rarely occurring C-methylrotenoid on HMGB1-induced septic responses in vitro and in vivo.
    Yang EJ; Lee W; Song KS; Bae JS
    Biochem Pharmacol; 2016 Jun; 110-111():58-70. PubMed ID: 27106082
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The cytokine activity of HMGB1.
    Yang H; Wang H; Czura CJ; Tracey KJ
    J Leukoc Biol; 2005 Jul; 78(1):1-8. PubMed ID: 15734795
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.